Testing for lower respiratory diseases, particularly those causing pneumonia, is paramount for comprehensive patient care and public health management. Accurate diagnosis of the causative agent, whether it be bacteria or viruses is essential for guiding appropriate treatment strategies. By identifying the specific pathogen responsible for the infection, healthcare providers can prescribe targeted antimicrobial therapy, minimizing unnecessary antibiotic use and optimizing patient outcomes.

​

Additionally, prompt diagnosis through testing facilitates early initiation of supportive measures, such as supplemental oxygen or respiratory therapies, which are critical for managing severe cases of pneumonia. Beyond individual patient care, testing for lower respiratory diseases plays a crucial role in public health surveillance efforts. Monitoring the prevalence and distribution of pneumonia-causing pathogens allows for timely implementation of infection control measures and targeted vaccination campaigns, helping to prevent outbreaks and reduce the burden of disease on communities.

​

The GeneFirst Multiplex Probe Amplification (MPA) technology enables real-time PCR detection of multiple targets within a closed-tube reaction.  This allows for high throughput testing of patients, supporting accurate and expedited disease management and the prevention of further spread.